研究单位：[1]The Third Affiliated Hospital of Southern Medical University[2]Xuanwu Hospital Capital Medical University Beijing,Beijing,China,100053[3]Xinqiao Hospital of Army Medical University Chongqing,Chongqing,China,400037[4]The First Hospital of Lanzhou University Lanzhou,Gansu,China,730000[5]Guangdong 999 Brain Hospital Guangzhou,Guangdong,China,510000[6]The Third Affiliated Hospital of Southern Medical University Guangzhou,Guangdong,China,510630[7]The Fifth Affiliated Hospital of Southern Medical University Guangzhou,Guangdong,China,510900[8]MaoMing People's Hospital Maoming,Guangdong,China,525000[9]The Second People's Hospital of Shenzhen Shenzhen,Guangdong,China,518035[10]Zhongshan People's Hospital Zhongshan,Guangdong,China,528400[11]The Fifth Affiliated Hospital Sun-yet sen University Zhuhai,Guangdong,China,519000[12]The People's Hospital of Guangxi Zhuang Autonomous Region Nanning,Guangxi,China,530021
研究目的：
This study evaluates safety and efficacy of analgesia-first minimal sedation as an early antihypertensive treatment for spontaneous intracerebral hemorrhage. The analgesia-first minimal sedation strategy relies on the remifentanil-mediated alleviation of pain-induced stress response and the antisympathetic activity of dexmedetomidine to restore the elevated blood pressure to normal level in patients with spontaneous intracerebral hemorrhage. This strategy allows rapid stabilization of blood pressure, and its use as a pre-treatment for patients on mechanical ventilation prior to painful procedures reduces blood pressure variability and thereby results in etiologic treatment. It is more effective in blood pressure control than conventional symptomatic antihypertensive treatment, reduces the incidence of early hematoma expansion and improves prognosis, ,lowers healthcare workers workload, increases patient adherence, and improves healthcare worker satisfaction.
